JAK2 and familial pancreatic carcinoma: In that study, one-hundred and twenty-seven pancreatic cancer patients with distant metastasis were randomly assigned for treatment with either the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib or a placebo in conjunction with a capecitabine treatment course.